Takeda licenses 2 drugs to NPS for as much as $80M

03/20/2013 | Genetic Engineering & Biotechnology News

Takeda Pharmaceutical granted NPS Pharmaceuticals complete global rights to develop and market its adult short bowel syndrome drug teduglutide and recombinant human parathyroid hormone 1-84, which is approved in Europe for post-menopausal osteoporosis. The deal covers all assets related to the two products. NPS will pay Takeda $50 million in common stock and a potential $30 million milestone fee.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
PacificSource
Bend, OR
Clinical Appeals RN
MJHS
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ